<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03485950</url>
  </required_header>
  <id_info>
    <org_study_id>2017-0729</org_study_id>
    <secondary_id>NCI-2018-00755</secondary_id>
    <secondary_id>2017-0729</secondary_id>
    <nct_id>NCT03485950</nct_id>
  </id_info>
  <brief_title>Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam</brief_title>
  <official_title>An Investigator Initiated, Phase II Single-Center, Randomized, Open-Label, Prospective, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftolozane-Tazobactam Plus Vancomycin, Linezolid Versus Standard of Care Plus Vancomycin, Linezolid as Empiric Therapy in Febrile Neutropenic Adults With Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if the study drug ceftolozane-tazobactam&#xD;
      is more effective in controlling febrile neutropenia (fever and low white blood cell counts)&#xD;
      than using approved antibiotics in patients with cancer. The safety of ceftolozane-tazobactam&#xD;
      will also be studied.&#xD;
&#xD;
      This is an investigational study. Ceftolozane-tazobactam is FDA approved and commercially&#xD;
      available to treat certain types of infections. It is not approved for the treatment of&#xD;
      febrile neutropenia, either by itself or in combination with other antibiotics. Its use to&#xD;
      treat febrile neutropenia is investigational.&#xD;
&#xD;
      All other antibiotics given on this study are FDA approved and commercially available for the&#xD;
      treatment of infections. However, only cefepime is specifically FDA approved to treat febrile&#xD;
      neutropenia. The study doctor can explain how the study drugs are designed to work.&#xD;
&#xD;
      Up to 100 participants will take part in this study. All will be enrolled at MD Anderson.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Groups and Study Drug Administration:&#xD;
&#xD;
      If participant is found to be eligible to take part in this study and participant agrees,&#xD;
      participant will be randomly assigned (as in the flip of a coin) to either receive either the&#xD;
      study drug (Group 1) or a standard treatment antibiotic (Group 2). This is done because no&#xD;
      one knows if one study group is better, the same, or worse than the other group. Both&#xD;
      participant and the study doctor will know what participant is receiving.&#xD;
&#xD;
      If participant is in Group 1, participant will receive ceftolozane-tazobactam by vein over 1&#xD;
      hour every 8 hours.&#xD;
&#xD;
      If participant is in Group 2, participant will receive a standard treatment antibiotic. This&#xD;
      may include one of the following 3 options:&#xD;
&#xD;
      cefepime by vein over about 30 minutes every 8 hours. meropenem by vein over about 30 minutes&#xD;
      every 8 hours. piperacillin/tazobactam by vein over about 1 hour every 6 hours.&#xD;
&#xD;
      Participant will receive the study drugs by vein for at least 3 days. After 3 days, if the&#xD;
      study doctor thinks it is in participant's best interest and participant is eligible,&#xD;
      participant may switch to receiving a different antibiotic either by mouth or by vein. The&#xD;
      study doctor will tell participant more about what antibiotic participant may begin to&#xD;
      receive, how it is administered, and its possible risks. If participant begins taking the&#xD;
      study drugs by mouth, the study doctor or study staff will tell participant how and when to&#xD;
      take each drug.&#xD;
&#xD;
      If the doctor thinks it is needed, participant will be given additional standard drugs to&#xD;
      help control the infection. Participant may ask the study staff for information about how the&#xD;
      drugs are given and their risks.&#xD;
&#xD;
      Length of Study:&#xD;
&#xD;
      Participant may receive the study drugs for up to 14 days. Participant will no longer be able&#xD;
      to receive the study drugs if the disease gets worse, if intolerable side effects occur, if&#xD;
      participant needs treatment that is not allowed on this study, or if participant is unable to&#xD;
      follow study directions.&#xD;
&#xD;
      Participation on this study will be over after the late follow-up visit.&#xD;
&#xD;
      Study Visits:&#xD;
&#xD;
      Participant will have the following tests/procedures while participant is in the hospital. If&#xD;
      participant begins to take the study drugs by mouth, participant will no longer have these&#xD;
      study visits.&#xD;
&#xD;
      Each day for up to 2 weeks, if the doctor thinks it is needed, blood (about 1 tablespoon) or&#xD;
      urine will be collected for routine tests.&#xD;
&#xD;
      Every 2 days for up to 2 weeks, blood (about 1 tablespoon) will be drawn to check for&#xD;
      infection. Participant will stop having these blood draws when there is no longer a sign of&#xD;
      infection and participant does not have a fever.&#xD;
&#xD;
      Twice each week for up to 2 weeks, participant will have a physical exam.&#xD;
&#xD;
      Follow-Up:&#xD;
&#xD;
      Within 72 hours (3 days) after participant's last dose of participant's assigned study&#xD;
      treatment and before starting the second antibiotic therapy (if applicable):&#xD;
&#xD;
      Participant will have a physical exam. Blood (about 1 tablespoon) and urine will be collected&#xD;
      for routine tests. If participant tested positive for infection at the beginning of the&#xD;
      study, blood (about 1 tablespoon) will be drawn to check for infection. The study doctor will&#xD;
      tell participant if participant will have this blood draw.&#xD;
&#xD;
      About 21-28 days (3-4 weeks) after participant's first dose of study drug, participant will&#xD;
      return to MD Anderson for the following tests/procedures:&#xD;
&#xD;
      Participant will have a physical exam. If participant tested positive for infection at the&#xD;
      beginning of the study, blood (about 1 tablespoon) will be drawn to check for infection. The&#xD;
      study doctor will tell participant if participant will have this blood draw.&#xD;
&#xD;
      If participant can become pregnant, blood (about 1 teaspoon) will be drawn for a pregnancy&#xD;
      test.&#xD;
&#xD;
      About 35-42 days (5-6 weeks) after participant's first dose of study drug, a member of the&#xD;
      study staff will call participant to ask about any new drugs participant may have started and&#xD;
      if participant is having any side effects. If participant is called, it should last about 10&#xD;
      minutes. If the doctor or study staff thinks it is needed, participant will be asked to come&#xD;
      back to the clinic for the following tests/procedures:&#xD;
&#xD;
      Participant will have a physical exam. If the doctor thinks it is needed, blood (about 1&#xD;
      tablespoon) will be drawn to check for infection.&#xD;
&#xD;
      At any of these follow-up visits, if participant's doctor thinks it is needed, participant&#xD;
      will have a chest x-ray or CT scan to check participant's lungs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 16, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Actual">May 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Favorable Clinical Response at End of Inpatient Intravenous Therapy (EOIV)</measure>
    <time_frame>Within 72 hours after administration of the last dose of inpatient IV study drug</time_frame>
    <description>Resolution of all acute signs and symptoms of the primary infection or improvement to such an extent that no additional antibacterial therapy is required (ie, except for protocol-allowed adjunctive therapies and/or oral or IV switch) and such that no more than 14 days of total antibacterial therapy is required.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Favorable Clinical Response in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set at EOIV.</measure>
    <time_frame>Within 72 hours after administration of the last dose of inpatient IV study drug.</time_frame>
    <description>The secondary efficacy outcome is favorable clinical response of the patients in the mMITT (Microbiological Modified Intent-To-Treat) Analysis Set at end of inpatient intravenous therapy (EOIV). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Favorable Clinical Response in the Clinically Evaluable (CE) Analysis Set at EOIV.</measure>
    <time_frame>Within 72 hours after administration of the last dose of inpatient IV study drug.</time_frame>
    <description>The secondary efficacy outcome is favorable clinical response of the patients in the CE (Clinically Evaluable) Analysis Set at end of inpatient intravenous therapy (EOIV). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Favorable Clinical Response in the MITT Analysis Set at TOC</measure>
    <time_frame>21 to 28 days after the start of inpatient IV study drug</time_frame>
    <description>The secondary efficacy outcome is favorable clinical response of the patients in the MITT (Modified Intent-To-Treat) Analysis Set at test-of-cure (TOC). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Favorable Clinical Response in the MITT Analysis Set at Late Follow-Up (LFU)</measure>
    <time_frame>35 to 42 days after the start of inpatient IV study drug</time_frame>
    <description>The secondary efficacy outcome is favorable clinical response of the patients in the MITT (Modified Intent-To-Treat) Analysis Set at late follow-up (LFU). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Favorable Clinical Response in the mMITT Analysis Set at Test of Cure (TOC)</measure>
    <time_frame>21 to 28 days after the start of inpatient IV study drug.</time_frame>
    <description>The secondary efficacy outcome is favorable clinical response of the patients in the mMITT (Microbiological Modified Intent-To-Treat) Analysis Set at test-of-cure (TOC). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Favorable Clinical Response in the mMITT Analysis Set at Late Follow-Up (LFU)</measure>
    <time_frame>35 to 42 days after the start of inpatient IV study drug</time_frame>
    <description>The secondary efficacy outcome is favorable clinical response of the patients in the mMITT (Microbiological Modified Intent-To-Treat) Analysis Set at late follow-up (LFU). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Favorable Clinical Response in the CE Analysis Set at TOC</measure>
    <time_frame>21 to 28 days after the start of inpatient IV study drug</time_frame>
    <description>The secondary efficacy outcome is favorable clinical response of the patients in the CE (Clinically Evaluable) Analysis Set at test-of-cure (TOC). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Favorable Clinical Response in the CE Analysis Set at LFU.</measure>
    <time_frame>35 to 42 days after the start of inpatient IV study drug</time_frame>
    <description>The secondary efficacy outcome is favorable clinical response of the patients in the CE (Clinically Evaluable) Analysis Set at late follow-up (LFU). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Favorable Clinical Response in the ME Analysis Set at EOIV.</measure>
    <time_frame>Within 72 hours after administration of the last dose of inpatient IV study drug.</time_frame>
    <description>The secondary efficacy outcome is favorable clinical response of the patients in the ME (Microbiologically Evaluable) Analysis Set at end of inpatient intravenous therapy (EOIV). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Favorable Clinical Response in the ME Analysis Set at TOC</measure>
    <time_frame>21 to 28 days after the start of inpatient IV study drug.</time_frame>
    <description>The secondary efficacy outcome is favorable clinical response of the patients in the ME (Microbiologically Evaluable) Analysis Set at test-of-cure (TOC). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Favorable Clinical Response in the ME Analysis Set at LFU.</measure>
    <time_frame>35 to 42 days after the start of inpatient IV study drug</time_frame>
    <description>The secondary efficacy outcome is favorable clinical response of the patients in the ME (Microbiologically Evaluable) Analysis Set at late follow-up (LFU). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Favorable Microbiological Response in the mMITT Analysis Set at EOIV.</measure>
    <time_frame>Within 72 hours after administration of the last dose of inpatient IV study drug</time_frame>
    <description>The secondary efficacy outcome is favorable microbiological response of the patients in the mMITT (Microbiological Modified Intent-To-Treat) Analysis Set at end of inpatient intravenous therapy (EOIV). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Favorable Microbiological Response in the mMITT Analysis Set at TOC.</measure>
    <time_frame>21 to 28 days after the start of inpatient IV study drug</time_frame>
    <description>The secondary efficacy outcome is favorable microbiological response of the patients in the mMITT (Microbiological Modified Intent-To-Treat) Analysis Set at test-of-cure (TOC). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Favorable Microbiological Response in the mMITT Analysis Set at LFU.</measure>
    <time_frame>35 to 42 days after the start of inpatient IV study drug.</time_frame>
    <description>The secondary efficacy outcome is favorable microbiological response of the patients in the mMITT (Microbiological Modified Intent-To-Treat) Analysis Set at late follow-up (LFU). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Favorable Microbiological Response in the ME Analysis Set at EOIV.</measure>
    <time_frame>Within 72 hours after administration of the last dose of inpatient IV study drug</time_frame>
    <description>The secondary efficacy outcome is favorable clinical response of the patients in the ME (Microbiologically Evaluable) Analysis Set at end of inpatient intravenous therapy (EOIV). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Favorable Microbiological Response in the ME Analysis Set at TOC.</measure>
    <time_frame>21 to 28 days after the start of inpatient IV study drug</time_frame>
    <description>The secondary efficacy outcome is favorable microbiological response of the patients in the ME (Microbiologically Evaluable) Analysis Set at test-of-cure (TOC). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Favorable Microbiological Response in the ME Analysis Set at LFU</measure>
    <time_frame>35 to 42 days after the start of inpatient IV study drug</time_frame>
    <description>The secondary efficacy outcome is favorable microbiological response of the patients in the ME (Microbiologically Evaluable) Analysis Set at late follow-up (LFU). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Infection-related Mortality in the MITT Analysis Set at TOC</measure>
    <time_frame>21 to 28 days after the start of inpatient IV study drug</time_frame>
    <description>The secondary efficacy outcome is infection-related mortality of the patients in the MITT (Modified Intent-To-Treat) Analysis Set at test-of-cure (TOC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Infection-related Mortality in the MITT Analysis Set at LFU</measure>
    <time_frame>35 to 42 days after the start of inpatient IV study drug</time_frame>
    <description>The secondary efficacy outcome is infection-related mortality of the patients in the MITT (Modified Intent-To-Treat) Analysis Set at late follow-up (LFU).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Infection-related Mortality the mMITT Analysis Set at TOC</measure>
    <time_frame>21 to 28 days after the start of inpatient IV study drug</time_frame>
    <description>The secondary efficacy outcome is infection-related mortality of the patients in the mMITT (Microbiological Modified Intent-To-Treat) Analysis Set at test-of-cure (TOC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Infection-related Mortality in the mMITT Analysis Set at LFU.</measure>
    <time_frame>35 to 42 days after the start of inpatient IV study drug</time_frame>
    <description>The secondary efficacy outcome is infection-related mortality of the patients in the mMITT (Microbiological Modified Intent-To-Treat) Analysis Set at late follow-up (LFU).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30 Day All-cause Mortality in the MITT Analysis Set</measure>
    <time_frame>30 days after the last dose of inpatient IV study drug</time_frame>
    <description>The secondary efficacy outcome is all-cause mortality of the patients in the MITT (Modified Intent-To-Treat) Analysis Set, which is mortality within 30 days after the last dose of inpatient IV study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30 Day All-cause Mortality in the mMITT Analysis Set</measure>
    <time_frame>30 days after the last dose of inpatient IV study drug</time_frame>
    <description>The secondary efficacy outcome is all-cause mortality of the patients in the mMITT (microbiological Modified Intent-To-Treat) Analysis Set, which is mortality within 30 days after the last dose of inpatient IV study drug.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Other Infectious Diseases</condition>
  <arm_group>
    <arm_group_label>Group I (ceftolozane-tazobactam)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive ceftolozane-tazobactam IV over 1 hour every 8 hours for up to 14 days in the absence of disease progression or unacceptable toxicity. After at least 3 days, participants may switch to different PO or IV antibiotics at the discretion of the study doctor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II (standard of care antibiotic treatment)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive standard of care antibiotic treatment consisting of either cefepime IV over 30 minutes every 8 hours, meropenem IV over 30 minutes every 8 hours, or piperacillin-tazobactam IV over 1 hour every 6 hours for up to 14 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefepime</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group II (standard of care antibiotic treatment)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftolozane</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group I (ceftolozane-tazobactam)</arm_group_label>
    <other_name>CXA-101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Group I (ceftolozane-tazobactam)</arm_group_label>
    <arm_group_label>Group II (standard of care antibiotic treatment)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropenem</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group II (standard of care antibiotic treatment)</arm_group_label>
    <other_name>Meropenem Trihydrate</other_name>
    <other_name>Merrem I.V.</other_name>
    <other_name>SM-7338</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piperacillin-Tazobactam</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group II (standard of care antibiotic treatment)</arm_group_label>
    <other_name>PIPER/TAZO</other_name>
    <other_name>Piperacillin/Tazobactam</other_name>
    <other_name>Zosyn</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tazobactam</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group I (ceftolozane-tazobactam)</arm_group_label>
    <arm_group_label>Group II (standard of care antibiotic treatment)</arm_group_label>
    <other_name>YTR-830H</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has provided written informed consent, and has the willingness and ability to comply&#xD;
             with all study procedures&#xD;
&#xD;
          -  Patients with neutropenic fever who have existing malignancy or have undergone&#xD;
             hematopoietic stem cell transplantation; neutropenic fever is defined as the presence&#xD;
             of neutropenia defined by: 1) absolute neutrophil count (ANC) &lt; 500 cells/mm^3 or has&#xD;
             an ANC that is expected to decrease to &lt; 500 cells/mm^3 within 48 hours of trial entry&#xD;
             and fever defined as: 2) single oral temperature measurement of &gt; 101 degree&#xD;
             Fahrenheit (F) (38.3 degree Celsius [C]) or a temperature of &gt; 100.4 degree F (38.0&#xD;
             degree C) sustained over a 1-hour period&#xD;
&#xD;
          -  Requires hospitalization for IV empiric antibiotic therapy&#xD;
&#xD;
          -  If female: not breastfeeding; agrees to not attempt to become pregnant during the&#xD;
             study; is surgically sterile or at least 2-years postmenopausal, or if of childbearing&#xD;
             potential, has negative screening serum pregnancy test (if serum pregnancy test&#xD;
             results are not available at the time of enrollment, a negative urine pregnancy test&#xD;
             is required within 24 hours.); if of childbearing potential (including being &lt; 2 years&#xD;
             postmenopausal), is willing to practice sexual abstinence or use an effective dual&#xD;
             form of contraception with her partner (eg, 2 barrier methods, barrier method plus&#xD;
             hormonal method) during treatment and for â‰¥ 28 days after the last dose of any study&#xD;
             therapy (IV or oral)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of any hypersensitivity or allergic reaction to any cephalosporin antibiotic&#xD;
             or tazobactam&#xD;
&#xD;
          -  Fever suspected to be caused by a noninfectious cause (eg, fever related to drug or&#xD;
             blood product administration)&#xD;
&#xD;
          -  Confirmed fungal infection (eg, Pneumocystis jirovecii etiology in patients with&#xD;
             pneumonia) that justifies adding additional empiric antimicrobial therapy (eg,&#xD;
             antifungals)&#xD;
&#xD;
          -  Confirmed viral infection that justifies adding additional empiric antiviral therapy&#xD;
             (eg, ganciclovir, foscarnet)&#xD;
&#xD;
          -  Known acute viral hepatitis&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level &gt; 5 times the&#xD;
             upper limit of normal (x ULN); patients with values &gt; 3 x ULN and &lt; 5 x ULN are&#xD;
             eligible if the value is acute and directly related to the infectious process being&#xD;
             treated&#xD;
&#xD;
          -  Total bilirubin &gt; 3 x ULN unless isolated hyperbilirubinemia is directly related to&#xD;
             the acute infection or due to known Gilbert disease; manifestations of end-stage liver&#xD;
             disease, such as ascites or hepatic encephalopathy&#xD;
&#xD;
          -  Known to be human immunodeficiency virus positive&#xD;
&#xD;
          -  Severely impaired renal function, defined as creatinine clearance (CrCl) =&lt; 30 mL/min&#xD;
             estimated by the Cockcroft-Gault formula&#xD;
&#xD;
          -  Expected requirement for hemodialysis while on study therapy&#xD;
&#xD;
          -  Received &gt; 24 hours of IV antibacterial therapy (with study drugs) within 72 hours of&#xD;
             the initiation of inpatient IV study drug for treatment of suspected infection;&#xD;
             antibiotic prophylaxis and oral antibiotics is allowed; prophylactic use of antiviral&#xD;
             or antifungal medication is permitted&#xD;
&#xD;
          -  Requirement for any non-study potentially effective concomitant systemic antibacterial&#xD;
             therapy&#xD;
&#xD;
          -  Past or current history of epilepsy or seizure disorder; exception: well-documented&#xD;
             febrile seizure of childhood&#xD;
&#xD;
          -  Evidence of immediately life-threatening disease, progressively fatal disease, or life&#xD;
             expectancy of 3 months or less (eg, moribund or with shock unresponsive to fluid&#xD;
             replacement)&#xD;
&#xD;
          -  Unable or unwilling to adhere to the study-specified procedures and restrictions&#xD;
&#xD;
          -  Any condition that would make the patient, in the opinion of the investigator,&#xD;
             unsuitable for the study (eg, would place a patient at risk or compromise the quality&#xD;
             of the data&#xD;
&#xD;
          -  Participation in any other ongoing ceftolozane/tazobactam trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Issam I Raad</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 26, 2018</study_first_submitted>
  <study_first_submitted_qc>March 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2018</study_first_posted>
  <results_first_submitted>June 2, 2021</results_first_submitted>
  <results_first_submitted_qc>June 29, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 20, 2021</results_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Other infectious diseases</keyword>
  <keyword>Febrile neutropenic adults with cancer</keyword>
  <keyword>Ceftolozane-Tazobactam</keyword>
  <keyword>Cefepime</keyword>
  <keyword>Meropenem</keyword>
  <keyword>Piperacillin/Tazobactam</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Cefepime</mesh_term>
    <mesh_term>Piperacillin, Tazobactam Drug Combination</mesh_term>
    <mesh_term>Ceftolozane</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 16, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT03485950/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ceftolozane/Tazobactam Arm</title>
          <description>Received IV Ceftolozane/Tazobactam (minimum of 9 doses). Patients may receive other additional therapy.</description>
        </group>
        <group group_id="P2">
          <title>Standard of Care (SOC) Arm</title>
          <description>Received one of the following IV therapies: Cefepime (minimum of 9 doses), Meropenem (minimum of 9 doses), Piperacillin/Tazobactam (minimum of 12 doses). Patients may receive other additional therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients in Modified Intent-To-Treat (MITT) analysis set</population>
      <group_list>
        <group group_id="B1">
          <title>Ceftolozane/Tazobactam Arm</title>
          <description>Received IV Ceftolozane/Tazobactam (minimum of 9 doses). Patients may receive other additional therapy.</description>
        </group>
        <group group_id="B2">
          <title>Standard of Care (SOC) Arm</title>
          <description>Received one of the following IV therapies: Cefepime (minimum of 9 doses), Meropenem (minimum of 9 doses), Piperacillin/Tazobactam (minimum of 12 doses). Patients may receive other additional therapy.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="97"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="25" upper_limit="84"/>
                    <measurement group_id="B2" value="55" lower_limit="18" upper_limit="79"/>
                    <measurement group_id="B3" value="56" lower_limit="18" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Middle East</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Others</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of Hematological malignancy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Acute Lymphocytic Leukemia(ALL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic Lymphocytic Leukemia (AML)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic Myeloid Leukemia (CML)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Others</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Bone Marrow Transplant (BMT) within 1 year</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Autologous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Allogeneic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Temperature at initial presentation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt; 36 Celsius</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 -38 Celsius</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;38 Celsius</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Site of Microorganisms</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Genitourinary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Organism of positive culture</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Entereococcus faecalis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>E. coli</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Klebsiella pneumoniae</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Methicillin-resistant Staphylococcus aureus (MRSA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pseudomonas aeruginosa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rothia mucilaginous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Streptococcus viridans</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Staphylococcus epidermidis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Entereococcus faecalis + E coli</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Enterococcus faecalis + Pseudomonas aeruginosa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Temperature at baseline</title>
          <units>Celsius</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.3" lower_limit="36.9" upper_limit="38.2"/>
                    <measurement group_id="B2" value="37.5" lower_limit="37.0" upper_limit="38.3"/>
                    <measurement group_id="B3" value="37.4" lower_limit="37.0" upper_limit="38.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Microbiology Documentation</title>
          <description>Site of Microorganisms</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Genitourinary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genitourinary and Blood</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bacterial Pathogen Causing Documented Infection</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Gram Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gram Negative and Gram Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gram Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Favorable Clinical Response at End of Inpatient Intravenous Therapy (EOIV)</title>
        <description>Resolution of all acute signs and symptoms of the primary infection or improvement to such an extent that no additional antibacterial therapy is required (ie, except for protocol-allowed adjunctive therapies and/or oral or IV switch) and such that no more than 14 days of total antibacterial therapy is required.</description>
        <time_frame>Within 72 hours after administration of the last dose of inpatient IV study drug</time_frame>
        <population>Patients in MITT (Modified Intent-To-Treat) Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam Arm</title>
            <description>Received IV Ceftolozane/Tazobactam (minimum of 9 doses). Patients may receive other additional therapy.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (SOC) Arm</title>
            <description>Received one of the following IV therapies: Cefepime (minimum of 9 doses), Meropenem (minimum of 9 doses), Piperacillin/Tazobactam (minimum of 12 doses). Patients may receive other additional therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Favorable Clinical Response at End of Inpatient Intravenous Therapy (EOIV)</title>
          <description>Resolution of all acute signs and symptoms of the primary infection or improvement to such an extent that no additional antibacterial therapy is required (ie, except for protocol-allowed adjunctive therapies and/or oral or IV switch) and such that no more than 14 days of total antibacterial therapy is required.</description>
          <population>Patients in MITT (Modified Intent-To-Treat) Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Favorable Clinical Response in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set at EOIV.</title>
        <description>The secondary efficacy outcome is favorable clinical response of the patients in the mMITT (Microbiological Modified Intent-To-Treat) Analysis Set at end of inpatient intravenous therapy (EOIV). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
        <time_frame>Within 72 hours after administration of the last dose of inpatient IV study drug.</time_frame>
        <population>Patients in mMITT (Microbiological Modified Intent-To-Treat) Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam Arm</title>
            <description>Received IV Ceftolozane/Tazobactam (minimum of 9 doses). Patients may receive other additional therapy.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (SOC) Arm</title>
            <description>Received one of the following IV therapies: Cefepime (minimum of 9 doses), Meropenem (minimum of 9 doses), Piperacillin/Tazobactam (minimum of 12 doses). Patients may receive other additional therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Favorable Clinical Response in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set at EOIV.</title>
          <description>The secondary efficacy outcome is favorable clinical response of the patients in the mMITT (Microbiological Modified Intent-To-Treat) Analysis Set at end of inpatient intravenous therapy (EOIV). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
          <population>Patients in mMITT (Microbiological Modified Intent-To-Treat) Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Favorable Clinical Response in the Clinically Evaluable (CE) Analysis Set at EOIV.</title>
        <description>The secondary efficacy outcome is favorable clinical response of the patients in the CE (Clinically Evaluable) Analysis Set at end of inpatient intravenous therapy (EOIV). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
        <time_frame>Within 72 hours after administration of the last dose of inpatient IV study drug.</time_frame>
        <population>Patients in CE (Clinically Evaluable) Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam Arm</title>
            <description>Received IV Ceftolozane/Tazobactam (minimum of 9 doses). Patients may receive other additional therapy.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (SOC) Arm</title>
            <description>Received one of the following IV therapies: Cefepime (minimum of 9 doses), Meropenem (minimum of 9 doses), Piperacillin/Tazobactam (minimum of 12 doses). Patients may receive other additional therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Favorable Clinical Response in the Clinically Evaluable (CE) Analysis Set at EOIV.</title>
          <description>The secondary efficacy outcome is favorable clinical response of the patients in the CE (Clinically Evaluable) Analysis Set at end of inpatient intravenous therapy (EOIV). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
          <population>Patients in CE (Clinically Evaluable) Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Favorable Clinical Response in the MITT Analysis Set at TOC</title>
        <description>The secondary efficacy outcome is favorable clinical response of the patients in the MITT (Modified Intent-To-Treat) Analysis Set at test-of-cure (TOC). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
        <time_frame>21 to 28 days after the start of inpatient IV study drug</time_frame>
        <population>Patients in the MITT (Modified Intent-To-Treat) Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam Arm</title>
            <description>Received IV Ceftolozane/Tazobactam (minimum of 9 doses). Patients may receive other additional therapy.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (SOC) Arm</title>
            <description>Received one of the following IV therapies: Cefepime (minimum of 9 doses), Meropenem (minimum of 9 doses), Piperacillin/Tazobactam (minimum of 12 doses). Patients may receive other additional therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Favorable Clinical Response in the MITT Analysis Set at TOC</title>
          <description>The secondary efficacy outcome is favorable clinical response of the patients in the MITT (Modified Intent-To-Treat) Analysis Set at test-of-cure (TOC). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
          <population>Patients in the MITT (Modified Intent-To-Treat) Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Favorable Clinical Response in the MITT Analysis Set at Late Follow-Up (LFU)</title>
        <description>The secondary efficacy outcome is favorable clinical response of the patients in the MITT (Modified Intent-To-Treat) Analysis Set at late follow-up (LFU). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
        <time_frame>35 to 42 days after the start of inpatient IV study drug</time_frame>
        <population>Patients in the MITT (Modified Intent-To-Treat) Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam Arm</title>
            <description>Received IV Ceftolozane/Tazobactam (minimum of 9 doses). Patients may receive other additional therapy.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (SOC) Arm</title>
            <description>Received one of the following IV therapies: Cefepime (minimum of 9 doses), Meropenem (minimum of 9 doses), Piperacillin/Tazobactam (minimum of 12 doses). Patients may receive other additional therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Favorable Clinical Response in the MITT Analysis Set at Late Follow-Up (LFU)</title>
          <description>The secondary efficacy outcome is favorable clinical response of the patients in the MITT (Modified Intent-To-Treat) Analysis Set at late follow-up (LFU). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
          <population>Patients in the MITT (Modified Intent-To-Treat) Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Favorable Clinical Response in the mMITT Analysis Set at Test of Cure (TOC)</title>
        <description>The secondary efficacy outcome is favorable clinical response of the patients in the mMITT (Microbiological Modified Intent-To-Treat) Analysis Set at test-of-cure (TOC). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
        <time_frame>21 to 28 days after the start of inpatient IV study drug.</time_frame>
        <population>Patients in mMITT (Microbiological Modified Intent-To-Treat) Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam Arm</title>
            <description>Received IV Ceftolozane/Tazobactam (minimum of 9 doses). Patients may receive other additional therapy.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (SOC) Arm</title>
            <description>Received one of the following IV therapies: Cefepime (minimum of 9 doses), Meropenem (minimum of 9 doses), Piperacillin/Tazobactam (minimum of 12 doses). Patients may receive other additional therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Favorable Clinical Response in the mMITT Analysis Set at Test of Cure (TOC)</title>
          <description>The secondary efficacy outcome is favorable clinical response of the patients in the mMITT (Microbiological Modified Intent-To-Treat) Analysis Set at test-of-cure (TOC). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
          <population>Patients in mMITT (Microbiological Modified Intent-To-Treat) Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Favorable Clinical Response in the mMITT Analysis Set at Late Follow-Up (LFU)</title>
        <description>The secondary efficacy outcome is favorable clinical response of the patients in the mMITT (Microbiological Modified Intent-To-Treat) Analysis Set at late follow-up (LFU). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
        <time_frame>35 to 42 days after the start of inpatient IV study drug</time_frame>
        <population>Patients in mMITT (Microbiological Modified Intent-To-Treat) Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam Arm</title>
            <description>Received IV Ceftolozane/Tazobactam (minimum of 9 doses). Patients may receive other additional therapy.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (SOC) Arm</title>
            <description>Received one of the following IV therapies: Cefepime (minimum of 9 doses), Meropenem (minimum of 9 doses), Piperacillin/Tazobactam (minimum of 12 doses). Patients may receive other additional therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Favorable Clinical Response in the mMITT Analysis Set at Late Follow-Up (LFU)</title>
          <description>The secondary efficacy outcome is favorable clinical response of the patients in the mMITT (Microbiological Modified Intent-To-Treat) Analysis Set at late follow-up (LFU). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
          <population>Patients in mMITT (Microbiological Modified Intent-To-Treat) Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Favorable Clinical Response in the CE Analysis Set at TOC</title>
        <description>The secondary efficacy outcome is favorable clinical response of the patients in the CE (Clinically Evaluable) Analysis Set at test-of-cure (TOC). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
        <time_frame>21 to 28 days after the start of inpatient IV study drug</time_frame>
        <population>Patients in CE (Clinically Evaluable) Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam Arm</title>
            <description>Received IV Ceftolozane/Tazobactam (minimum of 9 doses). Patients may receive other additional therapy.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (SOC) Arm</title>
            <description>Received one of the following IV therapies: Cefepime (minimum of 9 doses), Meropenem (minimum of 9 doses), Piperacillin/Tazobactam (minimum of 12 doses). Patients may receive other additional therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Favorable Clinical Response in the CE Analysis Set at TOC</title>
          <description>The secondary efficacy outcome is favorable clinical response of the patients in the CE (Clinically Evaluable) Analysis Set at test-of-cure (TOC). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
          <population>Patients in CE (Clinically Evaluable) Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Favorable Clinical Response in the CE Analysis Set at LFU.</title>
        <description>The secondary efficacy outcome is favorable clinical response of the patients in the CE (Clinically Evaluable) Analysis Set at late follow-up (LFU). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
        <time_frame>35 to 42 days after the start of inpatient IV study drug</time_frame>
        <population>Patients in CE (Clinically Evaluable) Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam Arm</title>
            <description>Received IV Ceftolozane/Tazobactam (minimum of 9 doses). Patients may receive other additional therapy.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (SOC) Arm</title>
            <description>Received one of the following IV therapies: Cefepime (minimum of 9 doses), Meropenem (minimum of 9 doses), Piperacillin/Tazobactam (minimum of 12 doses). Patients may receive other additional therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Favorable Clinical Response in the CE Analysis Set at LFU.</title>
          <description>The secondary efficacy outcome is favorable clinical response of the patients in the CE (Clinically Evaluable) Analysis Set at late follow-up (LFU). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
          <population>Patients in CE (Clinically Evaluable) Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Favorable Clinical Response in the ME Analysis Set at EOIV.</title>
        <description>The secondary efficacy outcome is favorable clinical response of the patients in the ME (Microbiologically Evaluable) Analysis Set at end of inpatient intravenous therapy (EOIV). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
        <time_frame>Within 72 hours after administration of the last dose of inpatient IV study drug.</time_frame>
        <population>Patients in CE analysis set with baseline Gram-negative pathogen (= ME (Microbiologically Evaluable) Analysis Set)</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam Arm</title>
            <description>Received IV Ceftolozane/Tazobactam (minimum of 9 doses). Patients may receive other additional therapy.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (SOC) Arm</title>
            <description>Received one of the following IV therapies: Cefepime (minimum of 9 doses), Meropenem (minimum of 9 doses), Piperacillin/Tazobactam (minimum of 12 doses). Patients may receive other additional therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Favorable Clinical Response in the ME Analysis Set at EOIV.</title>
          <description>The secondary efficacy outcome is favorable clinical response of the patients in the ME (Microbiologically Evaluable) Analysis Set at end of inpatient intravenous therapy (EOIV). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
          <population>Patients in CE analysis set with baseline Gram-negative pathogen (= ME (Microbiologically Evaluable) Analysis Set)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Favorable Clinical Response in the ME Analysis Set at TOC</title>
        <description>The secondary efficacy outcome is favorable clinical response of the patients in the ME (Microbiologically Evaluable) Analysis Set at test-of-cure (TOC). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
        <time_frame>21 to 28 days after the start of inpatient IV study drug.</time_frame>
        <population>Patients in CE analysis set with baseline Gram-negative pathogen (= ME (Microbiologically Evaluable) Analysis Set)</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam Arm</title>
            <description>Received IV Ceftolozane/Tazobactam (minimum of 9 doses). Patients may receive other additional therapy.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (SOC) Arm</title>
            <description>Received one of the following IV therapies: Cefepime (minimum of 9 doses), Meropenem (minimum of 9 doses), Piperacillin/Tazobactam (minimum of 12 doses). Patients may receive other additional therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Favorable Clinical Response in the ME Analysis Set at TOC</title>
          <description>The secondary efficacy outcome is favorable clinical response of the patients in the ME (Microbiologically Evaluable) Analysis Set at test-of-cure (TOC). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
          <population>Patients in CE analysis set with baseline Gram-negative pathogen (= ME (Microbiologically Evaluable) Analysis Set)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Favorable Clinical Response in the ME Analysis Set at LFU.</title>
        <description>The secondary efficacy outcome is favorable clinical response of the patients in the ME (Microbiologically Evaluable) Analysis Set at late follow-up (LFU). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
        <time_frame>35 to 42 days after the start of inpatient IV study drug</time_frame>
        <population>Patients in CE analysis set with baseline Gram-negative pathogen (= ME (Microbiologically Evaluable) Analysis Set)</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam Arm</title>
            <description>Received IV Ceftolozane/Tazobactam (minimum of 9 doses). Patients may receive other additional therapy.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (SOC) Arm</title>
            <description>Received one of the following IV therapies: Cefepime (minimum of 9 doses), Meropenem (minimum of 9 doses), Piperacillin/Tazobactam (minimum of 12 doses). Patients may receive other additional therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Favorable Clinical Response in the ME Analysis Set at LFU.</title>
          <description>The secondary efficacy outcome is favorable clinical response of the patients in the ME (Microbiologically Evaluable) Analysis Set at late follow-up (LFU). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
          <population>Patients in CE analysis set with baseline Gram-negative pathogen (= ME (Microbiologically Evaluable) Analysis Set)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Favorable Microbiological Response in the mMITT Analysis Set at EOIV.</title>
        <description>The secondary efficacy outcome is favorable microbiological response of the patients in the mMITT (Microbiological Modified Intent-To-Treat) Analysis Set at end of inpatient intravenous therapy (EOIV). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
        <time_frame>Within 72 hours after administration of the last dose of inpatient IV study drug</time_frame>
        <population>Patients in mMITT (Microbiological Modified Intent-To-Treat) Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam Arm</title>
            <description>Received IV Ceftolozane/Tazobactam (minimum of 9 doses). Patients may receive other additional therapy.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (SOC) Arm</title>
            <description>Received one of the following IV therapies: Cefepime (minimum of 9 doses), Meropenem (minimum of 9 doses), Piperacillin/Tazobactam (minimum of 12 doses). Patients may receive other additional therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Favorable Microbiological Response in the mMITT Analysis Set at EOIV.</title>
          <description>The secondary efficacy outcome is favorable microbiological response of the patients in the mMITT (Microbiological Modified Intent-To-Treat) Analysis Set at end of inpatient intravenous therapy (EOIV). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
          <population>Patients in mMITT (Microbiological Modified Intent-To-Treat) Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Favorable Microbiological Response in the mMITT Analysis Set at TOC.</title>
        <description>The secondary efficacy outcome is favorable microbiological response of the patients in the mMITT (Microbiological Modified Intent-To-Treat) Analysis Set at test-of-cure (TOC). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
        <time_frame>21 to 28 days after the start of inpatient IV study drug</time_frame>
        <population>Patients in mMITT (Microbiological Modified Intent-To-Treat) Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam Arm</title>
            <description>Received IV Ceftolozane/Tazobactam (minimum of 9 doses). Patients may receive other additional therapy.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (SOC) Arm</title>
            <description>Received one of the following IV therapies: Cefepime (minimum of 9 doses), Meropenem (minimum of 9 doses), Piperacillin/Tazobactam (minimum of 12 doses). Patients may receive other additional therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Favorable Microbiological Response in the mMITT Analysis Set at TOC.</title>
          <description>The secondary efficacy outcome is favorable microbiological response of the patients in the mMITT (Microbiological Modified Intent-To-Treat) Analysis Set at test-of-cure (TOC). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
          <population>Patients in mMITT (Microbiological Modified Intent-To-Treat) Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Favorable Microbiological Response in the mMITT Analysis Set at LFU.</title>
        <description>The secondary efficacy outcome is favorable microbiological response of the patients in the mMITT (Microbiological Modified Intent-To-Treat) Analysis Set at late follow-up (LFU). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
        <time_frame>35 to 42 days after the start of inpatient IV study drug.</time_frame>
        <population>Patients in mMITT (Microbiological Modified Intent-To-Treat) Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam Arm</title>
            <description>Received IV Ceftolozane/Tazobactam (minimum of 9 doses). Patients may receive other additional therapy.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (SOC) Arm</title>
            <description>Received one of the following IV therapies: Cefepime (minimum of 9 doses), Meropenem (minimum of 9 doses), Piperacillin/Tazobactam (minimum of 12 doses). Patients may receive other additional therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Favorable Microbiological Response in the mMITT Analysis Set at LFU.</title>
          <description>The secondary efficacy outcome is favorable microbiological response of the patients in the mMITT (Microbiological Modified Intent-To-Treat) Analysis Set at late follow-up (LFU). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
          <population>Patients in mMITT (Microbiological Modified Intent-To-Treat) Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Favorable Microbiological Response in the ME Analysis Set at EOIV.</title>
        <description>The secondary efficacy outcome is favorable clinical response of the patients in the ME (Microbiologically Evaluable) Analysis Set at end of inpatient intravenous therapy (EOIV). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
        <time_frame>Within 72 hours after administration of the last dose of inpatient IV study drug</time_frame>
        <population>Patients in ME (Microbiologically Evaluable) Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam Arm</title>
            <description>Received IV Ceftolozane/Tazobactam (minimum of 9 doses). Patients may receive other additional therapy.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (SOC) Arm</title>
            <description>Received one of the following IV therapies: Cefepime (minimum of 9 doses), Meropenem (minimum of 9 doses), Piperacillin/Tazobactam (minimum of 12 doses). Patients may receive other additional therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Favorable Microbiological Response in the ME Analysis Set at EOIV.</title>
          <description>The secondary efficacy outcome is favorable clinical response of the patients in the ME (Microbiologically Evaluable) Analysis Set at end of inpatient intravenous therapy (EOIV). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
          <population>Patients in ME (Microbiologically Evaluable) Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Favorable Microbiological Response in the ME Analysis Set at TOC.</title>
        <description>The secondary efficacy outcome is favorable microbiological response of the patients in the ME (Microbiologically Evaluable) Analysis Set at test-of-cure (TOC). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
        <time_frame>21 to 28 days after the start of inpatient IV study drug</time_frame>
        <population>Patients in ME (Microbiologically Evaluable) Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam Arm</title>
            <description>Received IV Ceftolozane/Tazobactam (minimum of 9 doses). Patients may receive other additional therapy.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (SOC) Arm</title>
            <description>Received one of the following IV therapies: Cefepime (minimum of 9 doses), Meropenem (minimum of 9 doses), Piperacillin/Tazobactam (minimum of 12 doses). Patients may receive other additional therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Favorable Microbiological Response in the ME Analysis Set at TOC.</title>
          <description>The secondary efficacy outcome is favorable microbiological response of the patients in the ME (Microbiologically Evaluable) Analysis Set at test-of-cure (TOC). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
          <population>Patients in ME (Microbiologically Evaluable) Analysis Set.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Favorable Microbiological Response in the ME Analysis Set at LFU</title>
        <description>The secondary efficacy outcome is favorable microbiological response of the patients in the ME (Microbiologically Evaluable) Analysis Set at late follow-up (LFU). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
        <time_frame>35 to 42 days after the start of inpatient IV study drug</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam Arm</title>
            <description>Received IV Ceftolozane/Tazobactam (minimum of 9 doses). Patients may receive other additional therapy.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (SOC) Arm</title>
            <description>Received one of the following IV therapies: Cefepime (minimum of 9 doses), Meropenem (minimum of 9 doses), Piperacillin/Tazobactam (minimum of 12 doses). Patients may receive other additional therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Favorable Microbiological Response in the ME Analysis Set at LFU</title>
          <description>The secondary efficacy outcome is favorable microbiological response of the patients in the ME (Microbiologically Evaluable) Analysis Set at late follow-up (LFU). The clinical outcome has three categories: Favorable clinical response, Clinical failure, and Indeterminate.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Infection-related Mortality in the MITT Analysis Set at TOC</title>
        <description>The secondary efficacy outcome is infection-related mortality of the patients in the MITT (Modified Intent-To-Treat) Analysis Set at test-of-cure (TOC).</description>
        <time_frame>21 to 28 days after the start of inpatient IV study drug</time_frame>
        <population>Patients in MITT (Modified Intent-To-Treat) Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam Arm</title>
            <description>Received IV Ceftolozane/Tazobactam (minimum of 9 doses). Patients may receive other additional therapy.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (SOC) Arm</title>
            <description>Received one of the following IV therapies: Cefepime (minimum of 9 doses), Meropenem (minimum of 9 doses), Piperacillin/Tazobactam (minimum of 12 doses). Patients may receive other additional therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Infection-related Mortality in the MITT Analysis Set at TOC</title>
          <description>The secondary efficacy outcome is infection-related mortality of the patients in the MITT (Modified Intent-To-Treat) Analysis Set at test-of-cure (TOC).</description>
          <population>Patients in MITT (Modified Intent-To-Treat) Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Infection-related Mortality in the MITT Analysis Set at LFU</title>
        <description>The secondary efficacy outcome is infection-related mortality of the patients in the MITT (Modified Intent-To-Treat) Analysis Set at late follow-up (LFU).</description>
        <time_frame>35 to 42 days after the start of inpatient IV study drug</time_frame>
        <population>Patients in MITT (Modified Intent-to-Treat) Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam Arm</title>
            <description>Received IV Ceftolozane/Tazobactam (minimum of 9 doses). Patients may receive other additional therapy.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (SOC) Arm</title>
            <description>Received one of the following IV therapies: Cefepime (minimum of 9 doses), Meropenem (minimum of 9 doses), Piperacillin/Tazobactam (minimum of 12 doses). Patients may receive other additional therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Infection-related Mortality in the MITT Analysis Set at LFU</title>
          <description>The secondary efficacy outcome is infection-related mortality of the patients in the MITT (Modified Intent-To-Treat) Analysis Set at late follow-up (LFU).</description>
          <population>Patients in MITT (Modified Intent-to-Treat) Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Infection-related Mortality the mMITT Analysis Set at TOC</title>
        <description>The secondary efficacy outcome is infection-related mortality of the patients in the mMITT (Microbiological Modified Intent-To-Treat) Analysis Set at test-of-cure (TOC).</description>
        <time_frame>21 to 28 days after the start of inpatient IV study drug</time_frame>
        <population>Patients in mMITT (Microbiological Modified Intent-To-Treat) Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam Arm</title>
            <description>Received IV Ceftolozane/Tazobactam (minimum of 9 doses). Patients may receive other additional therapy.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (SOC) Arm</title>
            <description>Received one of the following IV therapies: Cefepime (minimum of 9 doses), Meropenem (minimum of 9 doses), Piperacillin/Tazobactam (minimum of 12 doses). Patients may receive other additional therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Infection-related Mortality the mMITT Analysis Set at TOC</title>
          <description>The secondary efficacy outcome is infection-related mortality of the patients in the mMITT (Microbiological Modified Intent-To-Treat) Analysis Set at test-of-cure (TOC).</description>
          <population>Patients in mMITT (Microbiological Modified Intent-To-Treat) Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Infection-related Mortality in the mMITT Analysis Set at LFU.</title>
        <description>The secondary efficacy outcome is infection-related mortality of the patients in the mMITT (Microbiological Modified Intent-To-Treat) Analysis Set at late follow-up (LFU).</description>
        <time_frame>35 to 42 days after the start of inpatient IV study drug</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam Arm</title>
            <description>Received IV Ceftolozane/Tazobactam (minimum of 9 doses). Patients may receive other additional therapy.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (SOC) Arm</title>
            <description>Received one of the following IV therapies: Cefepime (minimum of 9 doses), Meropenem (minimum of 9 doses), Piperacillin/Tazobactam (minimum of 12 doses). Patients may receive other additional therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Infection-related Mortality in the mMITT Analysis Set at LFU.</title>
          <description>The secondary efficacy outcome is infection-related mortality of the patients in the mMITT (Microbiological Modified Intent-To-Treat) Analysis Set at late follow-up (LFU).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>30 Day All-cause Mortality in the MITT Analysis Set</title>
        <description>The secondary efficacy outcome is all-cause mortality of the patients in the MITT (Modified Intent-To-Treat) Analysis Set, which is mortality within 30 days after the last dose of inpatient IV study drug.</description>
        <time_frame>30 days after the last dose of inpatient IV study drug</time_frame>
        <population>Patients in MITT (Modified Intent-To-Treat) Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam Arm</title>
            <description>Received IV Ceftolozane/Tazobactam (minimum of 9 doses). Patients may receive other additional therapy.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (SOC) Arm</title>
            <description>Received one of the following IV therapies: Cefepime (minimum of 9 doses), Meropenem (minimum of 9 doses), Piperacillin/Tazobactam (minimum of 12 doses). Patients may receive other additional therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>30 Day All-cause Mortality in the MITT Analysis Set</title>
          <description>The secondary efficacy outcome is all-cause mortality of the patients in the MITT (Modified Intent-To-Treat) Analysis Set, which is mortality within 30 days after the last dose of inpatient IV study drug.</description>
          <population>Patients in MITT (Modified Intent-To-Treat) Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>30 Day All-cause Mortality in the mMITT Analysis Set</title>
        <description>The secondary efficacy outcome is all-cause mortality of the patients in the mMITT (microbiological Modified Intent-To-Treat) Analysis Set, which is mortality within 30 days after the last dose of inpatient IV study drug.</description>
        <time_frame>30 days after the last dose of inpatient IV study drug</time_frame>
        <population>Patients in mMITT (Modified Intent-To-Treat) Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam Arm</title>
            <description>Received IV Ceftolozane/Tazobactam (minimum of 9 doses). Patients may receive other additional therapy.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (SOC) Arm</title>
            <description>Received one of the following IV therapies: Cefepime (minimum of 9 doses), Meropenem (minimum of 9 doses), Piperacillin/Tazobactam (minimum of 12 doses). Patients may receive other additional therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>30 Day All-cause Mortality in the mMITT Analysis Set</title>
          <description>The secondary efficacy outcome is all-cause mortality of the patients in the mMITT (microbiological Modified Intent-To-Treat) Analysis Set, which is mortality within 30 days after the last dose of inpatient IV study drug.</description>
          <population>Patients in mMITT (Modified Intent-To-Treat) Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the date of the first dose of IV study drug to 30 days following the last dose of study drug. All patients were followed until last follow up which occurred 35-42 days following the first dose of study drug.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ceftolozane/Tazobactam Arm</title>
          <description>Received IV Ceftolozane/Tazobactam (minimum of 9 doses). Patients may receive other additional therapy.</description>
        </group>
        <group group_id="E2">
          <title>Standard of Care (SOC) Arm</title>
          <description>Received one of the following IV therapies: Cefepime (minimum of 9 doses), Meropenem (minimum of 9 doses), Piperacillin/Tazobactam (minimum of 12 doses). Patients may receive other additional therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Heart failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Papilledema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Retroperitoneal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Bloodstream infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Splenic infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Viral hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Vascular access complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Intracranial hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>ALT elevation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Issam Raad,MD - Chair, Infectious Diseases</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>(713) 792-7943</phone>
      <email>iraad@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

